One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Introduction : To overcome the blood-brain barrier (BBB) which interferes with the effect of chemotherapeutic agents, we performed multiple disruption of BBB (BBBD) with magnetic resonance-guided focused ultrasound (MRgFUS) on patients with glioblastoma (GBM) during standard adjuvant temozolomide (TMZ) chemotherapy. We report a one-year follow-up result of BBBD with TMZ for GBM. Methods: From September 2018 to January 2019, six patients were enrolled (4 men and 2 women, mean age: 55.83±11.03 years). Of the six patients, five underwent a total of 6 cycles of BBBD during standard TMZ adjuvant therapy. One patient underwent 3 cycles of BBBD but continued with TMZ chemotherapy. The one-year follow-up results of these 6 patients were reviewed. Results: The mean follow-up duration was 15.17±1.72 months. Two patients showed recurrence of tumor at 11 months and 16 months, respectively. One underwent surgery, and the other patient was restarted with TMZ chemotherapy due to the tumor location with highly possibility of surgical complications. The survival rate up to 1 year was 100% and the other four patients are on observation without recurrence. None of the six patients had immediate or delayed BBBD-related complications. Conclusion: Multiple BBBDs can be regarded as a safe procedure without long-term complication and it seems to have some survival benefits. However, since TMZ partially crosses the BBB, further extended study with large numbers would be needed to evaluate the benefits of BBBD resulting in an increase of TMZ concentration. This study opened a new therapeutic strategy for GBM by combining BBBD with a therapeutic agent which could not be used due to BBB.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Blood-brain barrier opening in Alzheimer’s disease using MR-guided focused ultrasound
Lipsman, N., Meng, Y., Bethune, A. J., Huang, Y., Lam, B., Masellis, M., Herrmann, N., Heyn, C., Aubert, I., Boutet, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04529-6 · Cited by 950
Cited by
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Wang, J., Li, Z., Pan, M., Fiaz, M., Hao, Y., Yan, Y., Sun, L., & Yan, F. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114539 · Cited by 161
Applications of focused ultrasound-mediated blood-brain barrier opening
Gorick, C. M., Breza, V. R., Nowak, K. M., Cheng, V. W. T., Fisher, D. G., Debski, A. C., Hoch, M. R., Demir, Z. E. F., Tran, N. M., Schwartz, M. R., et al. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114583 · Cited by 144
Zhu, H., Allwin, C., Bassous, M. G., & Pouliopoulos, A. N. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04795-z · Cited by 75
“Side effects generally diminish with steroid treatment [29], and resolved within 1 to 48 h in one study [27].”
BackgroundMethodInfluentialEpelbaum, S., Burgos, N., Canney, M., Matthews, D., Houot, M., Santin, M. D., Desseaux, C., Bouchoux, G., Stroer, S., Martin, C., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-00981-1 · Cited by 72
Metadata
- Authors
- Park, S. H., Kim, M. J., Jung, H. H., Chang, W. S., Choi, H. S., Rachmilevitch, I., Zadicario, E., & Chang, J. W.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-09-10
- Volume
- 10
- Pages
- 1663-1663
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3084799131
- Cited by
- 98
- References
- 2
- FWCI
- 4.92
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. https://app.cochat.ai/papers/10.3389/fonc.2020.01663
- The paper
- Park, S. H., Kim, M. J., Jung, H. H., Chang, W. S., Choi, H. S., Rachmilevitch, I., Zadicario, E., & Chang, J. W. (2020). One-Year Outcome of Multiple Blood–Brain Barrier Disruptions With Temozolomide for the Treatment of Glioblastoma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2020.01663
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.